Prodrugs of heteroaryl compounds

Abstract

The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.

1 . A method for treating Hepatitis C comprising the step of administering to a subject in need of such treatment a therapeutically effective amount of a compound having a structure according to Formula I: 
     
       
         
         
             
             
         
       
     
     wherein
 a is either 0 or 1; 
 b is either 0 or 1; 
 the dashed line represents a double bond between C* and N when a is 0; 
 wherein R 1  is a structure according to Formula II: 
 
     
       
         
         
             
             
         
       
     
     wherein
 the dashed line represents a double bond between C a  and C b ; 
 R 9 , R 10  and R 11  are members independently selected from H, —OH, —OR 12 , —NH 2 , —NO 2 , —SO 2 NH 2 , N 3 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
 R 2  is a member selected from (═O) and NR 7 R 8 , such that when R 2  is (═O), b is 0, and when R 2  is NR 7 R 8 , b is 1; 
 R 4  is a member selected from H, halogen, OR 3 , NR 7 R 8 , nitrile, and substituted and unsubstituted (C 1 -C 5 )alkyl; 
 R 6  is a member selected from H, halogen, substituted or unsubstituted O-alkyl, NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
 R 7 , R 8  and R 5  are members independently selected from H, OR 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
 R 3  is independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted acyl; 
 wherein R 7  and R 8  together with the nitrogen to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; 
 wherein R 8  and R 5  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; 
 wherein R 5  and R 6  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; 
 wherein R 12  is selected from an amino acid and a peptide comprising between 2 and 5 amino acids; 
 wherein R 9  and R 10  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; 
 wherein R 10  and R 11  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and 
 wherein at least one member selected from R 3 , R 5 , R 7 , and R 8 , alone or together with the atom to which it is covalently bonded, is selected from carbamate and urea linkers. 
 
   
   
       2 . The method according to  claim 1 , wherein R 2  is selected from (═O), —NH 2 , and —NHOH. 
   
   
       3 . The method according to  claim 1 , wherein R 4  is selected from F, CN, —CCH, —CCMe, and CH 3 . 
   
   
       4 . The method of  claim 1 , wherein R 1  comprises a hydroxyl moiety. 
   
   
       5 . The method of  claim 4 , wherein R 1  comprises a saccharyl moiety. 
   
   
       6 . The method according to  claim 1 , wherein R 9 , R 10  and R 11  are members independently selected from H, OH, (R 13 ) 3 SiO—, and a structure according to Formula III: 
     
       
         
         
             
             
         
       
       wherein each R 13  is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;
 wherein more than one R 13  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and 
 wherein R 16 , R 17 , and R 18  are independently selected from substituted and unsubstituted alkyl. 
 
     
   
   
       7 . The method of  claim 6 , wherein R 16 , R 17 , and R 18  are ethyl. 
   
   
       8 . The method according to  claim 1 , wherein R 3 , R 5 , R 7 , and R 8  are independently selected from H and a structure according to Formula IV: 
     
       
         
         
             
             
         
       
       wherein R 14  is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids; 
       wherein if R 8  is a structure according to Formula IV, then R 7  is H. 
     
   
   
       9 . The method according to  claim 1 , wherein R 3 , R 5 , R 7 , and R 8  are independently selected from H and a structure according to Formula V: 
     
       
         
         
             
             
         
       
       wherein R 15  is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids; 
       wherein if R 8  is a structure according to Formula V, then R 7  is H. 
     
   
   
       10 . The method according to  claim 8 , wherein R 14  is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol, 
     
       
         
         
             
             
         
       
     
   
   
       11 . The method according to  claim 9 , wherein R 15  is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol, 
     
       
         
         
             
             
         
       
     
   
   
       12 . The method according to  claim 10 , wherein R 14  is unsubstituted (C 6 -C 10 )alkyl. 
   
   
       13 . The method according to  claim 11 , wherein R 15  is unsubstituted (C 6 -C 10 )alkyl. 
   
   
       14 . The method according to  claim 8 , wherein R 2  is selected from (═O), —NH 2 , and —NHOH. 
   
   
       15 . The method according to  claim 9 , wherein R 2  is selected from (═O), —NH 2 , and —NHOH. 
   
   
       16 . The method according to  claim 8 , wherein R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 . 
   
   
       17 . The method according to  claim 9 , wherein R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 . 
   
   
       18 . The method according to  claim 10 , wherein
 R 2  is selected from (═O), —NH 2 , and —NHOH; and   R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .   
   
   
       19 . The method according to  claim 11 , wherein
 R 2  is selected from (═O), —NH 2 , and —NHOH; and   R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .   
   
   
       20 . The method of  claim 1 , wherein said compound is given orally. 
   
   
       21 . The method of  claim 20 , wherein said compound is an enteric formulation. 
   
   
       22 . The method of  claim 21 , wherein said compound is delivered in an osmotic oral delivery device.